Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.
Kirkland & Ellis offered legal advice to the financial advisor, China International Capital Corporation (CICC), in the deal.
Henlius, established in 2010, was listed in Hong Kong in September 2019. Its product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmic diseases. The company has launched five products in China and has three products approved for international markets. In 2023, the company achieved its first annual profit.
The Freshfields team was led by partners Edward Freeman, Grace Huang, and David Yi.
The Kirkland team was led by corporate partners Joey Chau and Nelson Ni, with assistance from debt finance partners Jacqueline Zheng and Sean Zhang.
